ASH 2018 | Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, discusses the results of the TOURMALINE-MM3 trial (NCT02181413) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Maintenance therapy with ixazomib, an oral proteasome inhibitor, was found to significantly prolong progression-free survival following autologous stem cell transplantation in newly diagnosed multiple myeloma.
Get great new content delivered to your inboxSign up